HAIXI PHARMA Shares Surge Over 4% in Morning Session as HXP056 Completes Phase I Enrollment and Initiates Phase II Study

Stock News03-25

HAIXI PHARMA (02637) saw its shares rise more than 4% during the morning trading session. At the time of writing, the stock was up 3.42%, trading at HKD 148, with a turnover of HKD 19.4604 million. The company announced that HXP056 commenced its Phase I clinical trial in Chinese patients with wAMD in early July 2025. Patient recruitment for both the Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) stages has been completed. Following four weeks of continuous dosing, the Dose-Limiting Toxicity (DLT) assessment and Pharmacokinetic (PK) data collection have been finalized. A preliminary efficacy evaluation is currently underway. In the fourth quarter of 2025, the company initiated a Phase II clinical dose expansion study. Notably, since March 9, HAIXI PHARMA has been officially included in the Hong Kong Stock Connect list. Mainland investors who meet the eligibility criteria can now directly trade the company's H-shares listed on the Hong Kong Stock Exchange through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect schemes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148445511?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 10:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148445511","market":"other","top_or_hot":-1,"title":"HAIXI PHARMA Shares Surge Over 4% in Morning Session as HXP056 Completes Phase I Enrollment and Initiates Phase II Study","media":"Stock News","content":"<p>HAIXI PHARMA (02637) saw its shares rise more than 4% during the morning trading session. At the time of writing, the stock was up 3.42%, trading at HKD 148, with a turnover of HKD 19.4604 million. The company announced that HXP056 commenced its Phase I clinical trial in Chinese patients with wAMD in early July 2025. Patient recruitment for both the Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) stages has been completed. Following four weeks of continuous dosing, the Dose-Limiting Toxicity (DLT) assessment and Pharmacokinetic (PK) data collection have been finalized. A preliminary efficacy evaluation is currently underway. In the fourth quarter of 2025, the company initiated a Phase II clinical dose expansion study. Notably, since March 9, HAIXI PHARMA has been officially included in the Hong Kong Stock Connect list. Mainland investors who meet the eligibility criteria can now directly trade the company's H-shares listed on the Hong Kong Stock Exchange through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect schemes.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HAIXI PHARMA Shares Surge Over 4% in Morning Session as HXP056 Completes Phase I Enrollment and Initiates Phase II Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHAIXI PHARMA Shares Surge Over 4% in Morning Session as HXP056 Completes Phase I Enrollment and Initiates Phase II Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-25 10:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HAIXI PHARMA (02637) saw its shares rise more than 4% during the morning trading session. At the time of writing, the stock was up 3.42%, trading at HKD 148, with a turnover of HKD 19.4604 million. The company announced that HXP056 commenced its Phase I clinical trial in Chinese patients with wAMD in early July 2025. Patient recruitment for both the Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) stages has been completed. Following four weeks of continuous dosing, the Dose-Limiting Toxicity (DLT) assessment and Pharmacokinetic (PK) data collection have been finalized. A preliminary efficacy evaluation is currently underway. In the fourth quarter of 2025, the company initiated a Phase II clinical dose expansion study. Notably, since March 9, HAIXI PHARMA has been officially included in the Hong Kong Stock Connect list. Mainland investors who meet the eligibility criteria can now directly trade the company's H-shares listed on the Hong Kong Stock Exchange through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect schemes.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1148445511","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148445511","pubTimestamp":1774406316,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HAIXI PHARMA (02637) saw its shares rise more than 4% during the morning trading session. At the time of writing, the stock was up 3.42%, trading at HKD 148, with a turnover of HKD 19.4604 million....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","02637":"海西新药","BK4588":"碎股","BK1191":"制药","BK4585":"ETF&股票定投概念"},"translate_title":"HXP056完成I期入组并启动II期研究，海西药业股价早盘飙升逾4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1,"VXUS":1},"content_text":"HAIXI PHARMA (02637) saw its shares rise more than 4% during the morning trading session. At the time of writing, the stock was up 3.42%, trading at HKD 148, with a turnover of HKD 19.4604 million. The company announced that HXP056 commenced its Phase I clinical trial in Chinese patients with wAMD in early July 2025. Patient recruitment for both the Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) stages has been completed. Following four weeks of continuous dosing, the Dose-Limiting Toxicity (DLT) assessment and Pharmacokinetic (PK) data collection have been finalized. A preliminary efficacy evaluation is currently underway. In the fourth quarter of 2025, the company initiated a Phase II clinical dose expansion study. Notably, since March 9, HAIXI PHARMA has been officially included in the Hong Kong Stock Connect list. Mainland investors who meet the eligibility criteria can now directly trade the company's H-shares listed on the Hong Kong Stock Exchange through the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect schemes.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148445511","isCrawlerRequest":true}